Evidence map›Paper›PMID 37085773›Full record

ArticleBMC neurology2023

Protocol of a randomized controlled trial investigating Deep Brain Stimulation for MOtor symptoms in patients with Parkinson's disease DEmentia (DBS-MODE).

V Sisodia, B E K S Swinnen, J M Dijk, E Verwijk, G van Rooijen, A W Lemstra, P R Schuurman, R M A de Bie

Abstract readClinical Trial Protocol
In one paragraph

Article in BMC neurology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

V SisodiaAmsterdam UMC location University of Amsterdam, Neurology, Meibergdreef 9, Amsterdam, Netherlands.
B E K S SwinnenAmsterdam UMC location University of Amsterdam, Neurology, Meibergdreef 9, Amsterdam, Netherlands.
J M DijkAmsterdam UMC location University of Amsterdam, Neurology, Meibergdreef 9, Amsterdam, Netherlands.
E VerwijkAmsterdam UMC location University of Amsterdam, Medical Psychology, Amsterdam, Netherlands.
G van RooijenAmsterdam Neuroscience, Neurodegeneration, Amsterdam, Netherlands.
A W LemstraAmsterdam Neuroscience, Neurodegeneration, Amsterdam, Netherlands.
P R SchuurmanAmsterdam Neuroscience, Neurodegeneration, Amsterdam, Netherlands.
R M A de BieAmsterdam UMC location University of Amsterdam, Neurology, Meibergdreef 9, Amsterdam, Netherlands. r.m.debie@amsterdamumc.nl.ORCID http://orcid.org/0000-0001-5267-0784

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundDeep brain stimulation (DBS) of the subthalamic nucleus (STN) is an established treatment for disabling motor symptoms of Parkinson's disease (PD) that persist despite optimal pharmacological treatment. Currently, DBS is not performed if there is concomitant significant cognitive impairment based on concerns of cognitive deterioration, higher complication rate and less functional improvement. However, this has not been investigated so far.

methodsA single center, prospective, randomized, open-label, blinded end-point (PROBE design) pilot clinical trial is being performed. Patients are eligible for the trial if they have PD dementia (PDD), are able to provide informed consent, and experience disabling motor response fluctuations, bradykinesia, dyskinesia, or painful dystonia, despite optimal pharmacological treatment. In total 44 patients will be randomized to either STN-DBS accompanied by best medical treatment (DBS group) or to best medical treatment alone (BMT group). The primary outcome measure is the change from baseline to 30 weeks on the Movement Disorder Society-Unified Parkinson's Disease Rating Scale part III score in a standardized off-drug phase. The main secondary outcome measures consist of scales assessing cognitive aspects of daily living, neuropsychiatric symptoms and impulsive compulsive disorders. Additional secondary outcome measures include motor signs during on-drug phase, dyskinesia, motor fluctuations, cognitive performance, (severe) adverse events, treatment satisfaction, and caregiver burden. Patients will be followed during 52 weeks after randomization. DISCUSSION: The Deep Brain Stimulation for MOtor symptoms in patients with Parkinson's disease DEmentia (DBS-MODE) trial directly compares the effectiveness and safety of DBS with BMT in patients with PDD.

trial registrationThe DBS-MODE trial has been registered in the International Clinical Trial Registry Platform (NL9361) on the 24

Indexed as

Alzheimer DiseaseDeep Brain StimulationDementiaDyskinesiasParkinson DiseaseHumansProspective StudiesRandomized Controlled Trials as TopicTreatment OutcomeDeep brain stimulationDementiaParkinson’s diseaseRandomized controlled trial

Identifiers

PMID37085773
PMCPMC10120102

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.